Bioventus Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Bioventus Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 11.8 times. Higher than 95% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Goodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative. Less tangible than 93% of Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 11% in 3 years; of every extra $100 of sales, $324 became extra profit. Higher than 90% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
11.8×Over the last 3 years its own operating cash covered its investment spending (capex) 11.8 times.
Higher than 95% of Healthcare companies in United States.
Cash Locked Ratio
$34For every $100 of sales, $34 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $35 tied up three years earlier.
More money tied up than 74% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 3/3Sales grew in 2 of the last 3 years; profit grew in 3 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$324Sales grew 11% in 3 years; of every extra $100 of sales, $324 became extra profit.
Higher than 90% of Healthcare companies in United States.
Asset Productivity Ratio
+11% / -50%In 3 years sales changed by +11% while total assets changed by -50%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
5.0×Debt due within a year is covered 5.0 times by its yearly operating cash.
Higher than 80% of Healthcare companies in United States.
Cash Cushion Ratio
−24%Debt, after subtracting cash, equals 24% of its market value (net debt).
Lower than 86% of Healthcare companies in United States.
Tangible Assets Ratio
45%Of every $100 the company owns, $45 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 84% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 93% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Bioventus Inc. owes $0.59 for every $1 it owns. Bioventus Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
19.2Investors pay $19.2 for every $1 of Bioventus Inc.'s yearly profit, lower than 65% of Healthcare companies in United States.
P/B ratio
4.48The share price is 4.48 times Bioventus Inc.'s book value per share, higher than 69% of Healthcare companies in United States.
Market cap
$1.0 BThe total market value of all of Bioventus Inc.'s shares at today's price (share price × number of shares), larger than 64% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$228 MWhat Bioventus Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.34Net worth divided by the number of shares. The share price of $14.96 is 4.5 times this, which is the P/B above.
Return on equity (ROE)
25.7%Bioventus Inc. earned 25.7% on its shareholders' money over the last year, higher than 93% of Healthcare companies in United States.
Owes vs Owns
0.59×Bioventus Inc. owes $0.59 for every $1 it owns (moderate), higher than 64% of Healthcare companies in United States.
Dividend yield
NoneBioventus Inc. does not currently pay a dividend.
Revenue growth
-1%Revenue fell 1% in the year to Dec 2025, and grew 4% a year on average over 3 years.
Profit growth
Back to profitBioventus Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
4.0%Bioventus Inc. keeps $4 of every $100 of revenue as net profit.
Cash quality
3.3×Cash from Bioventus Inc.'s business was 3.3× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
2.1×Bioventus Inc.'s operating profit covered its interest costs 2.1 times in the year to Dec 2025.
Cash vs debt
Net debtBioventus Inc. had $243 M more debt than cash (net debt) at Dec 2025.
Questions
What is Bioventus Inc.'s P/E ratio?
Investors pay $19.2 for every $1 of Bioventus Inc.'s yearly profit, lower than 65% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Bioventus Inc.: $1.0 B ÷ $228 M (30 Jun 2026) = 4.5.
What is Bioventus Inc.'s return on equity?
Bioventus Inc. earned 25.7% on its shareholders' money over the last year, higher than 93% of Healthcare companies in United States.
How much does Bioventus Inc. owe compared with what it owns?
Bioventus Inc. owes $0.59 for every $1 it owns (moderate), higher than 64% of Healthcare companies in United States.
Does Bioventus Inc. pay a dividend?
No. Bioventus Inc. does not currently pay a dividend.
Is Bioventus Inc.'s revenue growing?
Revenue fell 1% in the year to Dec 2025, and grew 4% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.